Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 25 | 2020 | 638 | 3.560 |
Why?
|
| Lung Neoplasms | 12 | 2020 | 409 | 3.010 |
Why?
|
| Radiosurgery | 19 | 2020 | 356 | 2.500 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2019 | 101 | 2.000 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 607 | 1.190 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 17 | 0.730 |
Why?
|
| Middle Aged | 31 | 2020 | 11845 | 0.690 |
Why?
|
| Syndecan-1 | 1 | 2019 | 11 | 0.690 |
Why?
|
| Plasma Cells | 1 | 2019 | 11 | 0.690 |
Why?
|
| Cystatin A | 1 | 2019 | 8 | 0.670 |
Why?
|
| Interleukin-23 Subunit p19 | 1 | 2019 | 11 | 0.660 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 45 | 0.650 |
Why?
|
| Glioma | 2 | 2011 | 136 | 0.650 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2018 | 7 | 0.650 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 20 | 0.650 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 53 | 0.630 |
Why?
|
| Carboplatin | 1 | 2018 | 48 | 0.630 |
Why?
|
| Paclitaxel | 1 | 2018 | 67 | 0.620 |
Why?
|
| Cranial Irradiation | 7 | 2020 | 93 | 0.620 |
Why?
|
| Female | 34 | 2020 | 19916 | 0.570 |
Why?
|
| Sulfides | 1 | 2016 | 27 | 0.560 |
Why?
|
| Caprylates | 1 | 2016 | 28 | 0.560 |
Why?
|
| Salvage Therapy | 8 | 2020 | 134 | 0.540 |
Why?
|
| Aged | 22 | 2020 | 10332 | 0.530 |
Why?
|
| Humans | 39 | 2020 | 31976 | 0.510 |
Why?
|
| Male | 29 | 2020 | 19155 | 0.510 |
Why?
|
| Lung | 1 | 2016 | 245 | 0.490 |
Why?
|
| Adult | 16 | 2020 | 9340 | 0.470 |
Why?
|
| Retrospective Studies | 17 | 2020 | 3523 | 0.420 |
Why?
|
| Prognosis | 10 | 2020 | 1505 | 0.410 |
Why?
|
| Procarbazine | 1 | 2011 | 5 | 0.400 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 36 | 0.390 |
Why?
|
| Thalidomide | 1 | 2011 | 31 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 370 | 0.380 |
Why?
|
| Program Development | 1 | 2011 | 96 | 0.370 |
Why?
|
| Research | 1 | 2011 | 74 | 0.370 |
Why?
|
| Internal Medicine | 1 | 2011 | 54 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 461 | 0.370 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 221 | 0.340 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 3998 | 0.340 |
Why?
|
| Curriculum | 1 | 2011 | 213 | 0.330 |
Why?
|
| Treatment Outcome | 11 | 2019 | 3314 | 0.330 |
Why?
|
| Microglia | 2 | 2020 | 57 | 0.330 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2009 | 29 | 0.330 |
Why?
|
| Neoplasms | 4 | 2020 | 692 | 0.310 |
Why?
|
| Survival Analysis | 7 | 2019 | 488 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2011 | 314 | 0.290 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 2279 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 154 | 0.280 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 725 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2019 | 261 | 0.250 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 311 | 0.250 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2004 | 12 | 0.250 |
Why?
|
| Pancreatitis | 1 | 2004 | 23 | 0.240 |
Why?
|
| Melanoma | 4 | 2019 | 164 | 0.240 |
Why?
|
| Breast Neoplasms | 4 | 2019 | 761 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 244 | 0.210 |
Why?
|
| Survival Rate | 3 | 2020 | 885 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 99 | 0.200 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 757 | 0.200 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 6 | 0.190 |
Why?
|
| Disease-Free Survival | 4 | 2018 | 319 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 74 | 0.180 |
Why?
|
| Prospective Studies | 3 | 2019 | 2282 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2018 | 1821 | 0.160 |
Why?
|
| Recurrence | 1 | 2019 | 265 | 0.160 |
Why?
|
| Serine Endopeptidases | 1 | 2018 | 20 | 0.160 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 35 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 100 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 19 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 54 | 0.160 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 31 | 0.160 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 4 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2019 | 180 | 0.160 |
Why?
|
| Nicotine | 1 | 2020 | 171 | 0.150 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2018 | 292 | 0.150 |
Why?
|
| Medicare | 1 | 2018 | 207 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 111 | 0.140 |
Why?
|
| Topotecan | 1 | 2016 | 17 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2020 | 682 | 0.140 |
Why?
|
| Granuloma | 1 | 2016 | 14 | 0.140 |
Why?
|
| MicroRNAs | 1 | 2018 | 180 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 391 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2016 | 106 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 82 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2016 | 80 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2018 | 598 | 0.120 |
Why?
|
| Age Factors | 1 | 2018 | 1191 | 0.120 |
Why?
|
| Appendiceal Neoplasms | 1 | 2015 | 98 | 0.120 |
Why?
|
| Mice | 4 | 2020 | 2472 | 0.110 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 170 | 0.110 |
Why?
|
| Genes, Immunoglobulin | 1 | 2013 | 4 | 0.110 |
Why?
|
| Major Histocompatibility Complex | 1 | 2013 | 16 | 0.110 |
Why?
|
| Smoking | 1 | 2017 | 496 | 0.110 |
Why?
|
| Mentors | 1 | 2011 | 31 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2011 | 186 | 0.090 |
Why?
|
| Receptor, erbB-2 | 2 | 2020 | 65 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2009 | 29 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2020 | 290 | 0.080 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 193 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2009 | 84 | 0.080 |
Why?
|
| Risk Factors | 4 | 2019 | 3867 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2018 | 142 | 0.080 |
Why?
|
| Animals | 4 | 2020 | 7459 | 0.080 |
Why?
|
| Mediastinum | 2 | 2018 | 14 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 300 | 0.070 |
Why?
|
| North Carolina | 1 | 2011 | 1516 | 0.070 |
Why?
|
| Radiation Injuries | 2 | 2016 | 72 | 0.060 |
Why?
|
| Quality of Life | 1 | 2011 | 933 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 564 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 485 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 878 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 322 | 0.050 |
Why?
|
| Anilides | 1 | 2020 | 10 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 19 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 6 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2020 | 30 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 21 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2020 | 25 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2020 | 66 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 25 | 0.050 |
Why?
|
| Pyridines | 1 | 2020 | 76 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 114 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2020 | 67 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 167 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 85 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 83 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 65 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 104 | 0.040 |
Why?
|
| Brain | 2 | 2018 | 949 | 0.040 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2019 | 18 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 319 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 148 | 0.040 |
Why?
|
| Astrocytes | 1 | 2019 | 58 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 20 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 98 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2018 | 189 | 0.040 |
Why?
|
| Nomograms | 1 | 2017 | 32 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 259 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 456 | 0.040 |
Why?
|
| Brain Death | 1 | 2017 | 27 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 733 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2017 | 149 | 0.040 |
Why?
|
| Retreatment | 1 | 2016 | 41 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 101 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 20 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 591 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 47 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1200 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2017 | 462 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2015 | 124 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 125 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 488 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 114 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 200 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 507 | 0.030 |
Why?
|
| Time Factors | 1 | 2017 | 2150 | 0.020 |
Why?
|
| United States | 1 | 2018 | 3936 | 0.020 |
Why?
|
| Troponin I | 1 | 2008 | 22 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 38 | 0.020 |
Why?
|
| Echocardiography | 1 | 2008 | 158 | 0.020 |
Why?
|